MNAP Diagnostics

MNAP Diagnostics is a biotechnology company specializing in the early detection and monitoring of cancer through a proprietary liquid biopsy platform. The company's technology focuses on identifying and quantifying Multi-Nucleated Atypical Polyploid (MNAP) cells, which are highly aggressive cancer cells found in the peripheral blood of patients with solid tumors. By targeting these specific biomarkers, MNAP Diagnostics aims to provide more accurate screening, prognosis, and treatment monitoring for various cancers, including prostate and breast cancer. The company was founded based on research from Johns Hopkins University and aims to improve patient outcomes by enabling earlier intervention. Their approach offers a non-invasive alternative to traditional tissue biopsies for assessing disease progression and treatment resistance.